A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
Completed · Phase 1 · Has a placebo group
Conditions studied: Parkinson's Disease
In brief
This two-part study will evaluate how safe LY3154207 is and the effects it has on the body. Part A will include healthy participants. Each participant will receive daily doses of LY3154207 or placebo for 14 days. Part A will last approximately 4 weeks including a 17 day stay in the clinical research unit (CRU) and follow-up. Part B is contingent on the results of Part A. Part B will include participants with Parkinson's disease. Each participant will receive daily doses of LY3154207 or placebo for 14 days. Part B will last approximately 4 weeks including a 17 day stay in the CRU and follow-up. Both Part A and Part B will require screening within 30 days prior to the start of the study.
Key facts
- Study ID
- NCT02562768
- Run by
- Eli Lilly and Company
- People needed
- 80
- Starts
- 2015-09-30
- Expected to finish
- 2017-03-03
- Last updated by the study team
- 2017-03-21
Who can join
Age: 20 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Part A:
- Overtly healthy males or females, as determined by medical history and physical examination
- Female participants not of child-bearing potential
- Part B:
- Have a clinical diagnosis of idiopathic Parkinson's disease for at least 1 year and on stable medication for at least 4 weeks
- Part A and B
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
- Have given written informed consent
- Have a body mass index (BMI) of 18.0 to 29.9 kilograms per square meter (kg/m²)
You may not qualify if…
- Have participated, in the last 30 days, in a clinical trial involving an investigational product
- Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; or constituting a risk when taking the study medication; or interfering with the interpretation of study data
Where it is running
- Parexel International LLC — Glendale, California, United States
- Compass Research — Orlanda, Florida, United States
- Compass Research — The Villages, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.